ASCO GI 2016: FOLFOX + ziv-aflibercept placebo versus AVAGAST trial of capecitabine-cisplatin with or without bevacizumab

Joel Randolph Hecht, MD of UCLA Health discusses FOLFOX + ziv-aflibercept placebo versus AVAGAST trial of capecitabine-cisplatin with or without bevacizumab at ASCO GI 2016 Author: ASCOGI2016 Added: 01/22/2016
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts